Highly B lymphocyte-specific tamoxifen inducible transgene expression of CreERT2 by using the LC-1 locus BAC vector

Genesis

Volumn 47, Issue 11, 2009, Pages 729-735

  Boross, Peter ^a   Breukel, Cor ^a   Van Loo, Pieter Fokko ^b   Van Der Kaa, Jos ^a   Claassens, Jill W ^a   Bujard, Hermann ^c   Schönig, Kai ^d   Verbeek, J Sjef ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

B cells; Cre recombinase; CreERT2; Somatic mutagenesis; Tamoxifen

Indexed keywords

CD19 ANTIGEN; CRE RECOMBINASE; FC RECEPTOR IIB; SUNFLOWER OIL; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BACTERIAL ARTIFICIAL CHROMOSOME; CONTROLLED STUDY; DNA RECOMBINATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; HEMIZYGOSITY; HOMOZYGOSITY; LIFE CYCLE; MOUSE; MOUSE STRAIN; MUTAGENESIS; NONHUMAN; POSITION EFFECT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; TRANSGENIC MOUSE; TRANSGENICS;

ANIMALS; ANTIGENS, CD19; B-LYMPHOCYTES; BASE SEQUENCE; CHROMOSOMES, ARTIFICIAL, BACTERIAL; DNA PRIMERS; GENE EXPRESSION REGULATION; HUMANS; INTEGRASES; MICE; MICE, TRANSGENIC; POLYMERASE CHAIN REACTION; TAMOXIFEN; TRANSGENES;

MUS; MUS MUSCULUS;

EID: 73249138340     PISSN: 1526954X     EISSN: 1526968X     Source Type: Journal    
DOI: 10.1002/dvg.20549     Document Type: Article

References (25)

1. Coezy E, Borgna JL, Rochefort H. 1982. Tamoxifen and metabolites in MCF7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 42:317-323.
2. Deenen GJ, Kroese FG. 1993. Kinetics of peritoneal B-1a cells (CD5 B cells) in young adult mice. Eur J Immunol 23:12-16.
3. Dorner T, Lipsky PE. 2006. Signalling pathways in B cells: Implications for autoimmunity. Curr Top Microbiol Immunol 305:213-240.
4. Feil R, Wagner J, Metzger D, Chambon P. 1997. Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains. Biochem Biophys Res Commun 237:752-757.
5. Hameyer D, Loonstra A, Eshkind L, Schmitt S, Antunes C, Groen A, Bindels E, Jonkers J, Krimpenfort P, Meuwissen R, Rijswijk L, Bex A, Berns A, Bockamp E. 2007. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol Genomics 31:32-41.
6. Hardy RR, Hayakawa K. 2001. B cell development pathways. Annu Rev Immunol 19:595-621.
7. Hobeika E, Thiemann S, Storch B, Jumaa H, Nielsen PJ, Pelanda R, Reth M. 2006. Testing gene function early in the B cell lineage in mb1-cre mice. Proc Natl Acad Sci USA 103:13789-13794.
8. Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, Metzger D. 1999. Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: Comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucleic Acids Res 27:4324-4327.
9. Jullien N, Sampieri F, Enjalbert A, Herman JP. 2003. Regulation of Cre recombinase by ligand-induced complementation of inactive fragments. Nucleic Acids Res 31:e131.
10. Kolber DL, Shultz LD, Rothstein TL. 1991. Phorbol ester responsiveness of murine Ly-1-lineage B cells from normal and viable motheaten mutant mice. Eur J Immunol 21:721-729.
11. Leonhard WN, Roelfsema JH, Lantinga-van LI, Breuning MH, Peters DJ. 2008. Quantification of Cre-mediated recombination by a novel strategy reveals a stable extra-chromosomal deletion-circle in mice. BMC Biotechnol 8:18.
12. Lewandoski M. 2001. Conditional control of gene expression in the mouse. Nat Rev Genet 2:743-755.
13. Liu P, Jenkins NA, Copeland NG. 2003. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res 13:476-484.
14. Lund FE. 2008. Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 20:332-338.
15. Lund FE, Garvy BA, Randall TD, Harris DP. 2005. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 8:25-54.
16. Maas A, Dingjan GM, Grosveld F, Hendriks RW. 1999. Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region. J Immunol 162:6526-6533.
17. Meffre E, Wardemann H. 2008. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 20:632-638.
18. Novak A, Guo C, Yang W, Nagy A, Lobe CG. 2000. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis 28:147-155.
19. Rickert RC, Roes J, Rajewsky K. 1997. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res 25:1317-1318.
20. Rui L, Goodnow CC. 2006. Lymphoma and the control of B cell growth and differentiation. Curr Mol Med 6:291-308.
21. Schmidt-Supprian M, Rajewsky K. 2007. Vagaries of conditional gene targeting. Nat Immunol 8:665-668.
22. Schönig K. 2003. Ph.D. Thesis, Universität Heidelberg.
23. Schönig K, Schwenk F, Rajewsky K, Bujard H. 2002. Stringent doxycycline dependent control of CRE recombinase in vivo. Nucleic Acids Res 30:e134.
24. Schwenk F, Kuhn R, Angrand PO, Rajewsky K, Stewart AF. 1998. Temporally and spatially regulated somatic mutagenesis in mice. Nucleic Acids Res 26:1427-1432.
25. Tarasenko T, Dean JA, Bolland S. 2007. FcgammaRIIB as a modulator of autoimmune disease susceptibility. Autoimmunity 40:409-417.